Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

190

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
M02AA10	ACHONID GEL	G	Ketoprofen - 2.5%	2.5%	Gel	179,179 L.L
M05BB03	ACIDE ALENDRONIQUE/ VITAMINE D3 BGR	G	Alendronic acid - 70mg, Colecalciferol - 5600UI		Tablet	815,712 L.L
D06AX01	ACIDE FUSIDIQUE BGR	G	Fusidic acid - 2%	2%	Cream	202,920 L.L
M05BA08	ACLASTA	B	Zoledronic acid (monohydrate) - 5mg/100ml	5mg/100ml	Injectable solution	21,075,062 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 80mg/4ml	80mg/4ml	Injectable concentrated solution	11,127,864 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 162mg/0.9ml	162mg/0.9ml	Injectable solution	79,959,812 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 200mg/10ml	200mg/10ml	Injectable concentrated solution	25,485,937 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 400mg/20ml	400mg/20ml	Injectable concentrated solution	47,925,322 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 80mg/4ml	80mg/4ml	Injectable concentrated solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 162mg/0.9ml	162mg/0.9ml	Injectable solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 200mg/10ml	200mg/10ml	Injectable concentrated solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 400mg/20ml	400mg/20ml	Injectable concentrated solution	L.L
J05AB01	ACTI-VIR	G	Aciclovir - 200mg	200mg	Tablet, scored	1,039,238 L.L
D06BB53	ACTI-VIR H	G	Aciclovir - 5%, Hydrocortisone acetate - 1%		Cream	833,182 L.L
A03E	ACTICARBINE	G	Activated charcoal - 70mg, Papaverine HCl - 14mg		Tablet, coated	311,771 L.L
B01AD02	ACTILYSE	BioTech	Alteplase - 50mg	50mg	Injectable dry powder for solution+diluent	100,976,426 L.L
N02AA01	ACTISKENAN	G	Morphine sulfate - 30mg	30mg	Capsule, immediate release	763,303 L.L
N02AA01	ACTISKENAN	G	Morphine sulfate - 20mg	20mg	Capsule, immediate release	512,004 L.L
N02AA01	ACTISKENAN	G	Morphine sulfate - 10mg	10mg	Capsule, immediate release	310,428 L.L
N02AA01	ACTISKENAN	G	Morphine sulfate - 5mg	5mg	Capsule, immediate release	233,829 L.L
R05X	ACTISOUFRE	B	Sulfure de Sodium - 13mg, Saccharomyces Cerevisiae - 500mg		Solution	740,457 L.L
A02AF02	ACTONORM	B	Aluminium hydroxide - 220mg/5ml, Magnesium hydroxide - 200mg/5ml, Simethicone - 25mg/5ml		Suspension	425,998 L.L
A10BG03	ACTOS	B	Pioglitazone HCl - 30mg	30mg	Tablet	2,484,765 L.L
A10BG03	ACTOS	B	Pioglitazone HCl - 15mg	15mg	Tablet	1,243,054 L.L
A10BD05	ACTOSMET	B	Metformin - 850mg, Pioglitazone - 15mg		Tablet, film coated	3,101,588 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
N02BG06	ACUPAN	B	Nefopam HCl - 20mg	20mg	Injectable solution	365,525 L.L
C09AA05	ACURIL	G	Ramipril - 2.5mg	2.5mg	Tablet	497,222 L.L
C09AA05	ACURIL	G	Ramipril - 5mg	5mg	Tablet	614,136 L.L

...

190